Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
J Am Coll Cardiol. 2011 Oct 11;58(16):1682-9. doi: 10.1016/j.jacc.2011.07.020.
We hypothesized that reductions in left atrial volume (LAV) with a cardiac resynchronization therapy-defibrillator (CRT-D) would translate into a subsequent reduction in the risk of atrial tachyarrhythmias (AT).
There is limited information regarding the effect of CRT-D on the risk of AT.
Percent reduction in LAV at 1 year following CRT-D implantation (pre-specified as low [lowest quartile: <20% reduction in LAV] and high [≥20% reduction in LAV] response to CRT-D) were related to the risk of subsequent AT (comprising atrial fibrillation, atrial flutter, atrial tachycardia, and supraventricular tachyarrhythmias) among patients enrolled in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
The cumulative probability of AT 2.5 years after assessment of echocardiographic response was lowest among high LAV responders to CRT-D (3%) and significantly higher among both low LAV responders to CRT-D (9%) and implantable cardioverter-defibrillator-only patients (7%; p = 0.03 for the difference among the 3 groups). Consistently, multivariate analysis showed that high LAV responders to CRT-D experienced a significant 53% (p = 0.01) reduction in the risk of subsequent AT as compared with implantable cardioverter-defibrillator-only patients, whereas low LAV responders did not derive a significant risk reduction with CRT-D therapy (hazard ratio [HR]: 1.05 [95% confidence interval (CI): 0.54 to 2.00]; p = 0.89). Patients who developed in-trial AT experienced significant increases in the risk for both the combined endpoint of heart failure or death (HR: 2.28 [95% CI: 1.45 to 3.59]; p < 0.001) and the separate occurrence of all-cause mortality (HR: 1.89 [95% CI: 1.08 to 3.62]; p = 0.01).
In the MADIT-CRT study, favorable reverse remodeling of the left atrium with CRT-D therapy was associated with a significant reduction in risk of subsequent AT. (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271).
我们假设心脏再同步治疗除颤器(CRT-D)治疗后左心房容积(LAV)的减少将转化为房性快速性心律失常(AT)风险的降低。
关于 CRT-D 对 AT 风险的影响,信息有限。
CRT-D 植入后 1 年 LAV 的百分比降低(预先指定为低[最低四分位数:LAV 减少<20%]和高[LAV 减少≥20%]对 CRT-D 的反应)与 MADIT-CRT(多中心自动除颤器植入试验与心脏再同步治疗)中纳入患者的随后 AT(包括房颤、房扑、房性心动过速和室上性心动过速)风险相关。
在评估超声心动图反应后 2.5 年,高 LAV 对 CRT-D 反应者的 AT 累积概率最低(3%),明显高于低 LAV 对 CRT-D 反应者(9%)和仅植入式心脏复律除颤器患者(7%;3 组之间差异的 p = 0.03)。同样,多变量分析显示,与仅植入式心脏复律除颤器患者相比,高 LAV 对 CRT-D 反应者的后续 AT 风险显著降低 53%(p = 0.01),而低 LAV 对 CRT-D 治疗者并未显著降低风险(风险比 [HR]:1.05 [95%置信区间(CI):0.54 至 2.00];p = 0.89)。在试验中发生 AT 的患者,心力衰竭或死亡的联合终点(HR:2.28 [95%CI:1.45 至 3.59];p <0.001)和全因死亡率的单独发生(HR:1.89 [95%CI:1.08 至 3.62];p = 0.01)的风险显著增加。
在 MADIT-CRT 研究中,CRT-D 治疗后左心房的有利逆向重构与随后 AT 风险的降低显著相关。(多中心自动除颤器植入试验与心脏再同步治疗 [MADIT-CRT];NCT00180271)。